<- Go Home
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Market Cap
$1.2B
Volume
283.7K
Cash and Equivalents
$55.1M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$28.00
52 Week Low
$6.57
Dividend
N/A
Price / Book Value
4.17
Price / Earnings
-11.87
Price / Tangible Book Value
4.17
Enterprise Value
$927.0M
Enterprise Value / EBITDA
-6.95
Operating Income
-$133.6M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$311.3M
Debt
$849.0K
Equity
$296.5M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A